Advertisement
Canada markets close in 5 hours 19 minutes

  • S&P/TSX

    21,996.14
    +124.18 (+0.57%)
     

  • S&P 500

    5,061.92
    +51.32 (+1.02%)
     

  • DOW

    38,447.80
    +207.82 (+0.54%)
     

  • CAD/USD

    0.7323
    +0.0022 (+0.30%)
     

  • CRUDE OIL

    82.23
    +0.33 (+0.40%)
     

  • Bitcoin CAD

    91,465.79
    +892.55 (+0.99%)
     

  • CMC Crypto 200

    1,439.69
    +24.93 (+1.76%)
     

  • GOLD FUTURES

    2,334.10
    -12.30 (-0.52%)
     

  • RUSSELL 2000

    1,998.39
    +30.92 (+1.57%)
     

  • 10-Yr Bond

    4.5820
    -0.0410 (-0.89%)
     

  • NASDAQ

    15,667.86
    +216.55 (+1.40%)
     

  • VOLATILITY

    16.29
    -0.65 (-3.84%)
     

  • FTSE

    8,034.72
    +10.85 (+0.14%)
     

  • NIKKEI 225

    37,552.16
    +113.55 (+0.30%)
     

  • CAD/EUR

    0.6836
    -0.0014 (-0.20%)
     
MARKETS LIVE BLOG:

STOCKS EXTEND GAINS AS RESULTS SEASON KICKS INTO HIGH GEAR

Tech-focused investors prepare for fresh wave of earnings highlighted by struggling Tesla

Graybug Vision to Participate in the 2021 Wedbush PacGrow Healthcare Virtual Conference

Graybug Vision, Inc.
·2 min read

REDWOOD CITY, Calif., Aug. 04, 2021 (GLOBE NEWSWIRE) -- Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve, today announced that Fred Guerard, PharmD, Chief Executive Officer of Graybug Vision, will participate in a panel discussion titled “Goldeneye” at the Wedbush PacGrow Healthcare Conference on Wednesday, August 11, 2021 at 9:45 a.m. ET / 6:45 a.m. PT.

A live webcast of the panel will be available in the Investors and Media section of the company’s website at https://investors.graybug.vision/news-events/events-presentations. Following the live webcast, a replay will be available at the same location for 14 days.

About Graybug

Graybug is a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of diseases of the retina and optic nerve. The company’s proprietary ocular delivery technologies are designed to maintain effective drug levels in ocular tissue for six months and potentially longer, improving disease management, reducing healthcare burdens and ultimately delivering better clinical outcomes. Graybug’s lead product candidate, GB-102, a formulation of the pan-vascular endothelial growth factor (VEGF) inhibitor, sunitinib malate targeting a six-month or longer dosing regimen, inhibits multiple neovascular pathways for the intravitreal treatment of retinal diseases, including wet age-related macular degeneration. Graybug’s other product candidates developed using its proprietary technologies also include GB-401, an injectable sustained-release formulation of a beta-adrenergic blocker prodrug, for primary open-angle glaucoma, with a dosing regimen of once every six months or longer, and GB-103, a longer-acting version of GB-102, designed to maintain therapeutic drug levels in the retinal tissue for 12 months with a single injection. Founded in 2011 on the basis of technology licensed from the Johns Hopkins University School of Medicine, Graybug is headquartered in Redwood City, California. For more information, please visit www.graybug.vision.

Investor Contact
IR@graybug.vision
(650) 487-2409

Media Contact
media@graybug.vision
(404) 384-0067